New research highlights potential of Huntington’s disease drug
Overall, patients who received tetrabenazin, which is currently being reviewed by the FDA, were six times as likely to be considered by their doctors to have improved considerably,
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.